Suven Life Sciences receives EIR from USFDA for its Pashamylaram facility

Suven Life Sciences has received the Establishment Inspection Report issued by the USFDA for its Pashamylaram facility. The facility was inspected from 21 October 2019 through 01 November 2019.

Based on this FDA inspection and the review thereafter, FDA has determined that the inspection classification of this facility as voluntary action indicated (VAI).

Suven Life Sciences has filed 22 DMF's, 6 ANDA's and 2 ANADA's from this facility which is FDA complaint under cGMP and continues after renewal inspection.

Powered by Capital Market - Live News